Triple-Drug attack before surgery aims to beat pancreatic cancer
NCT ID NCT07469956
First seen Mar 15, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This study tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. About 30 adults aged 18-75 will receive up to 8 cycles of treatment. The goal is to see if this approach improves survival and allows for complete tumor removal, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.